Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VALPROT 500XR
- Development stage
- Unknown
- Lead developer
- Asian Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VALPROT 500XR is an extended-release tablet formulation containing a combination of sodium valproate and valproic acid, manufactured by Asian Pharmaceuticals in Nepal. It is primarily indicated for the treatment of epilepsy and various seizure disorders. The drug functions as a broad-spectrum antiepileptic by enhancing GABAergic neurotransmission, likely through the inhibition of 4-aminobutyrate aminotransferase (GABA transaminase), and by modulating voltage-gated sodium channels and T-type calcium channels to reduce neuronal hyperexcitability. Kathmandu University has conducted randomized, open-label, crossover bioequivalence studies in healthy volunteers to compare VALPROT 500XR with innovator products, ensuring its pharmacokinetic profile supports clinical interchangeability and maintains seizure control.
- Brand names
- VALPROT 500XRVALPROT500XRVALPROT-500XR
- Other names
- sodium valproate + valproic acid extended releasesodium valproate and valproic acid
02
Targets
NaV (Voltage-gated sodium channels)HDAC (HDAC family)CaV3 (Caveolin-3)ABAT (4-aminobutyrate aminotransferase)SSADH (Succinate-semialdehyde dehydrogenase)
Beyond the preview
Go deeper on VALPROT 500XR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VALPROT 500XR.